- Report
- December 2023
- 182 Pages
Global
€4546EUR$4,995USD£3,861GBP
- Report
- August 2024
- 90 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- August 2024
- 96 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- May 2023
- 80 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- October 2022
- 94 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- June 2022
- 68 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- May 2022
- 166 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- May 2022
- 85 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- May 2022
- 74 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- April 2022
- 62 Pages
Global
From €1820EUR$2,000USD£1,546GBP
The Neuropathy Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat diseases and disorders of the brain, spinal cord, and peripheral nervous system. Neuropathy drugs are used to treat a variety of conditions, including diabetic neuropathy, postherpetic neuralgia, and chemotherapy-induced peripheral neuropathy. These drugs are typically administered orally, intravenously, or topically, and may include anticonvulsants, antidepressants, and opioids.
The Neuropathy Drug market is highly competitive, with a variety of companies offering products to treat a range of conditions. Some of the major players in the market include Pfizer, GlaxoSmithKline, Novartis, Merck, and Johnson & Johnson. Other companies, such as Eli Lilly, Sanofi, and AstraZeneca, also offer products in this market. Show Less Read more